Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258581 · ClinicalTrials.gov registry record
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A clinical trial, sponsored by Gilead Sciences.
- Terminated
- Registry status
- 241
- Enrollment target
NCT02258581 is a clinical trial that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 241 participants.
The verdict
NCT02258581 was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- 241 participants
- Enrollment target
Study Summary
This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only individuals who were treated in a Gilead-sponsored trial for chronic hepatitis B (CHB).
Interventions
- DRUG Tenofovir disoproxil fumarate (TDF)
- DRUG GS-4774
- DRUG GS-9620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2014-12-09 |
| Est. Completion | 2017-08-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02258581
The ClinicalTrials.gov registry entry for NCT02258581 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tenofovir disoproxil fumarate (TDF) is the first listed.
NCT02258581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02258581 about?
NCT02258581 is a clinical study titled "Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection". This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only individuals who were treated in a Gilead-sponsored trial for chronic hepatitis B (CHB).
What is the current status of trial NCT02258581?
This trial is currently terminated. The enrollment target is 241 participants. The study started on 2014-12-09. Estimated completion is 2017-08-14.
What interventions are being tested in trial NCT02258581?
The interventions under investigation include: Tenofovir disoproxil fumarate (TDF) (DRUG), GS-4774 (DRUG), GS-9620 (DRUG).
Who is sponsoring clinical trial NCT02258581?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.